Exploring the psychological impact of anxiety, depression, and quality of life in patients with comorbid disease conditions post COVID-19 pandemic era

Basit Öğe Kaydı
dc.contributor.authorAl-Taie, A.
dc.contributor.authorMohd Khalaf, D.A.
dc.contributor.authorArueyingho, O.
dc.date.accessioned2024-05-19T14:33:21Z
dc.date.available2024-05-19T14:33:21Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground: Chronic diseases and comorbidity are important predictors of depression and anxiety, the two most common disorders of poor mental health. Meanwhile, the pandemic increases anxiety and depression levels, alongside declined quality of life (QoL), the same way that comorbidities are associated with severity of COVID-19 progression. This study aimed to assess the prevalence of anxiety and depression, as well as the QoL among patients with chronic medical conditions in Amman, Jordan, in the post-pandemic period. Methods: A descriptive, cross-sectional study was conducted among patients with comorbidities using a validated questionnaire consisting of 3 parts. Anxiety and depression prevalence were assessed using the Hospital Anxiety and Depression Scale (HADS), while the QoL in terms of physical, psychological, social, emotional, and general mental health was evaluated using the SF-36 QoL questionnaire. Results: A total of 150 participants (mean age = 55 ± 13 years) were enrolled in the study. Most participants reported a significantly elevated level of borderline abnormal or mild anxiety (44%, P < .0001). The QoL scores indicated relatively poor well-being, particularly in the physical role (29.2 ± 45.5) and emotional role (26.2 ± 4.0) domains (P < .05). Statistical significance was observed between HADS anxiety or depression scores and variables, such as age, education level, and comorbidities. Conclusion: This study's findings provide insights into the adverse psychiatric consequences, high prevalence of anxiety and depressive symptoms, and reduced quality of life among patients with comorbid conditions post-COVID-19 pandemic. © 2023 Elsevier España, S.L.U.en_US
dc.identifier.doi10.1016/j.vacun.2023.08.005
dc.identifier.endpage53en_US
dc.identifier.issn1576-9887
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85179805863en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage46en_US
dc.identifier.urihttps://doi.org/10.1016/j.vacun.2023.08.005
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4200
dc.identifier.volume25en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherEdiciones Doyma, S.L.en_US
dc.relation.ispartofVacunasen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAnxietyen_US
dc.subjectComorbid Diseasesen_US
dc.subjectCovıd-19en_US
dc.subjectDepressionen_US
dc.subjectPandemicen_US
dc.subjectQuality Of Lifeen_US
dc.titleExploring the psychological impact of anxiety, depression, and quality of life in patients with comorbid disease conditions post COVID-19 pandemic eraen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu